Global Single-Channel Deep Brain Stimulation Device Market Research Report - Segmented By Application (Parkinson’s Disease, Epilepsy, Essential Tumors, Obsessive Compulsory Disorder, Dystonia, and Others); By End-use (Hospitals & Clinics, Ambulatory Surgical Centers, Neurological Clinics, Academic and Research Institutes, and Others); and Region - Size, Share, Growth Analysis | Forecast (2024 – 2030)

Single-Channel Deep Brain Stimulation Device Market Size (2024 –2030)

The Global Single-Channel Deep Brain Stimulation Device Market was estimated to be worth USD 2.19 Billion in 2023 and is projected to reach a value of USD 4.13 Billion by 2030, growing at a fast CAGR of 9.5% during the outlook period 2024-2030.

A medical device called a single-channel deep brain stimulation (DBS) device is used to treat neurological disorders such as dystonia, essential tremor, and Parkinson's disease. Through the use of an implanted electrode, this device sends electrical signals to particular brain regions. It consists of three main parts: an electrode inserted into the brain, a wire under the skin that connects the electrode to a pulse generator implanted close to the collarbone, and an electrode itself. To reduce symptoms, a medical professional programs the device to deliver electrical impulses at particular frequencies and intensities. A single-channel DBS device concentrates on stimulating a single area of the brain, as opposed to multi-channel devices that target multiple brain areas.

Key Market Insights:

Depending on the manufacturer and area, a single-channel DBS device's average selling price can vary from $15,000 to $25,000.Approximately 80,000 single-channel DBS devices are thought to be installed worldwide.Single-channel DBS devices usually have a battery life of three to five years, necessitating recurrent surgeries.About 70% of the market for single-channel DBS devices is driven by Parkinson's disease, with other neurological disorders accounting for the remaining demand.

Global Single-Channel Deep Brain Stimulation Device Market Drivers:

The increasing prevalence of neurological diseases like essential tremor, dystonia, epilepsy, Parkinson's disease, and obsessive-compulsive disorder can be treated with deep brain stimulation therapy.

In deep brain stimulation therapy, electrodes are surgically inserted into particular brain regions that regulate thought, emotion, and movement. These electrodes are attached to an implanted device in the abdomen or chest that resembles a pacemaker. The frequency and intensity of electrical stimulation applied to the brain are controlled by this apparatus. When medicine or other treatments don't work well for a neurological condition, deep brain stimulation is used to treat it. For instance, it can assist in the management of Parkinson's disease symptoms like slowness, stiffness, tremors, dyskinesia, or uncontrollable movements. It can also lessen muscle spasms and contractions in dystonia sufferers as well as tremors in other body parts like the hands, voice, or head in those with essential tremors.

Rechargeable and long-lasting devices are becoming more and more popular, which could lessen the need for routine battery replacement procedures and improve patient outcomes.

With a specialized recharger, rechargeable deep brain stimulation devices can be wirelessly charged from outside the body. These gadgets lessen the need for these uncomfortable and expensive battery replacement procedures. They offer more consistent and long-lasting treatment for patients who need high energy levels for ailments like dystonia or epilepsy. Additional flexibility and options for customizing stimulation settings are provided by rechargeable devices. They must be charged regularly, though, which may be bothersome to certain patients. Additionally, the recharger or implanted device may cause pain or skin irritation, and their cost may exceed that of non-rechargeable devices.

Single-Channel Deep Brain Stimulation Device Market Challenges and Restraints:

Therapies that are non-surgical or non-pharmacological can help patients with neurological disorders better manage their symptoms or function. These therapies serve as substitutes for surgery or prescription drugs. Medications that help with symptoms but may have interactions or side effects include mood stabilizers, antidepressants, anticonvulsants, antipsychotics, and pain relievers. Certain brain regions that are responsible for aberrant symptoms can be removed or destroyed during surgeries such as hemispherectomy, thalamotomy, pallidotomy, and lesioning. Other therapies that modulate brain activity through the scalp or neck use electrical or magnetic pulses, such as trigeminal nerve stimulation (TNS), vagus nerve stimulation (VNS), transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS).

Single-Channel Deep Brain Stimulation Device Market Opportunities:

Considerable room exists in the market for single-channel deep brain stimulation devices for growth and development. Technological developments in neurostimulation technologies have the potential to produce more sophisticated and useful devices, which will enhance patient outcomes and minimize side effects. Opportunities for market growth arise from entering emerging markets, where neurological disorders are becoming more common. The acceptance and demand for these devices can be increased by educating patients and healthcare professionals about the advantages of deep brain stimulation. Furthermore, by combining these gadgets with digital health platforms, overall patient care and remote monitoring capabilities can be strengthened, which will increase treatment results and patient satisfaction. The market for single-channel deep brain stimulation devices has room for growth and innovation because of all these factors combined.

SINGLE-CHANNEL DEEP BRAIN STIMULATION DEVICE MARKET REPORT COVERAGE:

Global Single-Channel Deep Brain Stimulation Device Market Segmentation: By Application

• Parkinson’s Disease

• Epilepsy

• Essential Tumors

• Obsessive Compulsory Disorder

• Dystonia

• Others

Due to the large number of afflicted individuals and the efficiency of deep brain stimulation in treating symptoms, the market for deep brain stimulation devices is being driven by Parkinson's disease. Parkinson's disease-related motor symptoms like tremors, stiffness, and slow movement can be lessened with deep brain stimulation. The epilepsy industry is growing quickly and is predicted to grow considerably in the upcoming years. The prevalence of epilepsy is rising, and drug-resistant varieties of the illness are being treated more and more with deep brain stimulation. Due to the effective application of deep brain stimulation in the treatment of conditions like essential tremors, dystonia, and obsessive-compulsive disorder, other segments of the market are also anticipated to grow steadily.

Global Single-Channel Deep Brain Stimulation Device Market Segmentation: By End-Use

• Hospitals & Clinics

• Ambulatory Surgical Centers

• Neurological Clinics

• Academic and Research Institutes

• Others

Thanks to their advanced medical resources and large patient base, hospitals and clinics are at the forefront of the deep brain stimulation device industry. Procedures for deep brain stimulation, which call for specific tools and knowledgeable medical personnel, are frequently carried out in clinics and hospitals. In the upcoming years, ambulatory surgery centers—which provide outpatient procedures at lower costs than hospitals and clinics—are anticipated to grow quickly. Academic and research institutions, neurological clinics, and other related sectors are anticipated to grow steadily as neurology research continues to grow and deep brain stimulation becomes more popular.

Global Single-Channel Deep Brain Stimulation Device Market Segmentation: By Region

• North America

• Europe

• Asia Pacific

• South America

• Middle East and Africa

The market for deep brain stimulation devices is dominated by North America because of the region's high prevalence of neurological disorders, cutting-edge hospitals, and significant business entities. North America's main market is the United States. Europe is closely behind, with nations like the United Kingdom, France, and Germany propelling market expansion via investments in neurology research and development and through expanding the use of deep brain stimulation therapy. This growth is a reflection of the increasing interest in and need for novel treatments in the European neurology market.

COVID-19 Impact on the Global Single-Channel Deep Brain Stimulation Device Market:

Deep brain stimulation demand and production have decreased as a result of the COVID-19 pandemic, which has also caused supply chain disruptions and increased financial strain on businesses. There are now fewer elective surgeries and treatments, such as deep brain stimulation therapy, as a result of lockdowns, travel restrictions, social distancing measures, and infection concerns. This has caused a shift in focus from neurological disorders to infectious diseases, impeding the development of new medical treatments and devices as well as diagnosis. But the pandemic has also brought about opportunities for the market, like the creation of longer-lasting and rechargeable devices that lessen the need for surgical battery replacements. Deep brain stimulation therapy and other minimally invasive procedures are becoming more popular and well-known.

Latest Trend/Development:

Current trends and advancements in the single-channel deep brain stimulation device market center on the advancement of technology to improve practicality and efficacy. To maximize patient outcomes, innovations include advancements in brain monitoring capabilities, wireless connectivity, and electrode design. A noticeable trend is the move toward wireless and rechargeable electronics, which allow for more flexible programming options and less frequent battery replacement. Real-time feedback and adaptive stimulation based on brain activity are made possible by the integration of brain-sensing technologies. Along with expanding the indications beyond Parkinson's disease to include essential tremor, dystonia, epilepsy, and psychiatric disorders, efforts are also being made towards miniaturization for less invasive surgeries. To improve patient care and treatment outcomes, clinical trials and regulatory developments are being conducted to expand the approved indications and facilitate a wider adoption of these devices across a range of neurological conditions.

Key Players:

1. Medtronic plc

2. Abbott (St. Jude Medical)

3. Boston Scientific Corporation

4. Aleva Neurotherapeutics S.A.

5. SceneRay Corporation

6. NeuroSigma Inc.

7. Renishaw PLC

8. LivaNova PLC

9. Neuropace Inc.

10. Beijing PINS Medical